DUBLIN--(BUSINESS WIRE)--Research and Markets (http://www.researchandmarkets.com/research/n246x5/acute) has announced the addition of the "Acute Inflammation - Pipeline Review, H1 2014" report to their offering.
This report provides comprehensive information on the therapeutic development for Acute Inflammation, complete with comparative analysis at various stages, therapeutics assessment by drug target, mechanism of action (MoA), route of administration (RoA) and molecule type, along with latest updates, and featured news and press releases. It also reviews key players involved in the therapeutic development for Acute Inflammation and special features on late-stage and discontinued projects.
The report enhances decision making capabilities and help to create effective counter strategies to gain competitive advantage. It strengthens R&D pipelines by identifying new targets and MOAs to produce first-in-class and best-in-class products.
Companies Involved in Therapeutics Development
- BioLineRx, Ltd.
- Actelion Ltd
- Forest Laboratories, Inc.
- Italfarmaco S.p.A.
- Alligator Bioscience AB
- Anacor Pharmaceuticals, Inc.
- Omeros Corporation
- Dompe Farmaceutici S.p.A.
- Peptinnovate Limited
- Selective Inhibitor of Pro Inflammatory Cytokine
- Small Molecule Targeting GPR32 for Acute Inflammation
- Distamycin Derivatives
For more information visit http://www.researchandmarkets.com/research/n246x5/acute